Welcome to our dedicated page for DICE Therapeutics news (Ticker: DICE), a resource for investors and traders seeking the latest updates and insights on DICE Therapeutics stock.
DICE Therapeutics, Inc. (NASDAQ: DICE) is a distinguished biopharmaceutical company renowned for leveraging its proprietary DELSCAPE technology platform to develop groundbreaking oral therapeutic candidates. Founded with a vision to revolutionize chronic disease treatment in the realm of immunology, DICE is dedicated to creating advanced oral treatments for autoimmune and inflammatory conditions.
The company's core technology, DELSCAPE, is designed to discover selective oral small molecules that can modulate protein-protein interactions (PPIs) as effectively as systemic biologics. This innovation is aimed at providing patients with convenient oral alternatives to traditional injectable therapies. DICE's lead therapeutic candidates include oral antagonists for the pro-inflammatory signaling molecule IL-17, which is a validated drug target implicated in a variety of immunological disorders.
DICE's notable projects include the development of oral IL-17 inhibitors such as DC-806 and DC-853, currently in clinical development, aimed at treating conditions like psoriasis and other autoimmune diseases. Additionally, the company is advancing oral therapeutic candidates targeting the integrin α4β7 for the treatment of inflammatory bowel disease, showcasing its commitment to addressing significant unmet medical needs.
In a strategic move to bolster its capabilities and market presence, DICE recently entered into a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY) for approximately $2.4 billion. This acquisition underscores the potential and value of DICE's innovative approaches and proprietary technology. Eli Lilly's extensive resources and global reach are expected to enhance the development and commercialization of DICE's therapeutic pipeline, accelerating the availability of these transformative treatments to patients worldwide.
Financially, the acquisition represents a premium of about 40% to DICE's 30-day volume-weighted average trading price, reflecting strong market confidence in DICE's future prospects. The transaction, approved by the boards of directors of both companies, is anticipated to close in the third quarter of 2023, pending customary closing conditions and regulatory approvals.
With a team of dedicated experts and a robust pipeline of oral therapeutics, DICE Therapeutics stands at the forefront of innovation in immunology, poised to make significant strides in improving patient outcomes for chronic and debilitating diseases.
DICE Therapeutics, Inc. (Nasdaq: DICE) reported its first quarter 2022 results, showing a cash position of $303.2 million, expected to fund operations through mid-2024. The company continues its Phase 1 clinical trial of oral IL-17 antagonist, DC-806, with topline proof-of-concept data anticipated in mid-2022. R&D expenses increased to $13.4 million from $6.6 million year-over-year, driven by advancements in the IL-17 franchise. The net loss for Q1 2022 was $18.6 million, a significant rise from $8.1 million in Q1 2021.
DICE Therapeutics, a biopharmaceutical company focusing on oral therapeutics for chronic diseases, will present at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 1:20 p.m. PT. The event will be accessible via a live and archived webcast on the Company’s website.
DICE is leveraging its DELSCAPE platform to develop oral candidates targeting IL-17, α4ß7 integrin, and αVß1/αVß6 integrin for conditions in immunology, inflammatory bowel disease, and idiopathic pulmonary fibrosis, aiming for comparable efficacy to systemic biologics.
ShouTi Inc., a clinical-stage biopharmaceutical company, has appointed Sharon Tetlow to its board of directors, where she will also chair the audit committee. With over 30 years of experience in life sciences finance, Tetlow has previously held senior roles including CFO at various biopharmaceutical firms. She currently serves on the boards of Dice Therapeutics (DICE), Valneva SE (VALN), and Catalyst Biosciences (CBIO). Her expertise is expected to strengthen ShouTi's growth strategy as the company focuses on developing innovative oral therapeutics for chronic diseases.
DICE Therapeutics, Inc. has appointed Mary Riley, J.D., as general counsel and added Lisa Bowers and Mittie Doyle, M.D., FACR, to its board of directors, enhancing its leadership team. Mary Riley brings 15 years of legal experience from Genentech, focusing on litigation and business law. Lisa Bowers, with a strong background in commercial leadership, and Mittie Doyle, a seasoned clinical development expert, will contribute significantly to DICE's biopharmaceutical initiatives. Concurrently, Stephen Zachary, Ph.D., has stepped down from the board. These changes aim to support DICE's growth in developing novel oral therapeutics targeting chronic diseases.
DICE Therapeutics, Inc. (Nasdaq: DICE) reported notable progress in its clinical trials and solid financial standing as of December 31, 2021. The company is on track to release topline data from its Phase 1 trial of oral IL-17 antagonist DC-806 in mid-2022, while DC-853 has been nominated as a new development candidate. DICE's cash position of $319.3 million is expected to sustain operations through mid-2024, supporting upcoming clinical milestones. However, R&D expenses increased significantly, resulting in a net loss of $49 million for 2021.
DICE Therapeutics, based in South San Francisco, has announced management's upcoming presentation at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 4:20 p.m. ET.
The company focuses on developing oral therapeutics for chronic diseases, particularly in immunology, using its proprietary DELSCAPE platform. DICE's lead candidate, S011806, targets IL-17, a molecule involved in inflammation. Interested parties can access a live and archived webcast of the presentation on their website for 90 days post-event.
DICE Therapeutics, a biopharmaceutical company focused on innovative oral therapeutics for chronic diseases, will participate in two investor conferences this November. Management will present at the 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22 at 10:00 a.m. ET, followed by a session at the 4th Annual Evercore ISI HealthCONx Conference on November 30 at 3:55 p.m. ET. Webcasts of both events will be available on the company's website. DICE is advancing oral candidates targeting significant immunology pathways, including IL-17, for enhanced therapeutic outcomes.
DICE Therapeutics (Nasdaq: DICE) successfully completed a $234.6 million upsized initial public offering, with 13,800,000 shares sold at $17.00 each. The company also dosed its first healthy volunteers in a Phase 1 clinical trial for S011806, an oral IL-17 antagonist aimed at treating psoriasis. DICE's cash and cash equivalents stand at $335.7 million, expected to fund operations through the end of 2023. R&D expenses rose to $11.7 million for Q3 2021, compared to $4.5 million in Q3 2020, reflecting increased personnel and preclinical advancement.
DICE Therapeutics (Nasdaq: DICE) announced the dosing of the first healthy volunteer in its Phase 1 clinical trial for S011806, an oral antagonist targeting IL-17, on October 25, 2021. This first-in-human trial aims to evaluate the safety, pharmacokinetics, and early efficacy of S011806 in psoriasis patients. With over 8 million Americans suffering from psoriasis, this trial represents a significant milestone in developing oral therapies for IL-17 mediated diseases. Successful outcomes could lead to S011806 becoming a viable alternative to injectable biologics.
DICE Therapeutics, Inc. announced the pricing of its upsized IPO, offering 12,000,000 shares at $17.00 each, aiming for gross proceeds of $204 million. All shares are offered by DICE, and trading on Nasdaq under the ticker symbol 'DICE' starts on September 15, 2021. The offering is set to close on September 17, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 1,800,000 more shares. The company focuses on developing novel oral therapeutics for chronic diseases in immunology.
FAQ
What is the market cap of DICE Therapeutics (DICE)?
What does DICE Therapeutics, Inc. specialize in?
What is DELSCAPE technology?
What are DICE's lead therapeutic candidates?
Who is acquiring DICE Therapeutics, Inc.?
What will be the impact of the acquisition by Eli Lilly?
What chronic diseases is DICE focusing on?
How does DICE's technology benefit patients?
What financial terms were agreed upon for the acquisition?
What are the expected closing conditions for the acquisition?
Where can I find more information about DICE's clinical developments?
